AUROPHARMA2021-04-012021-06-30in-bse-fin:OneOperatingExpenses01Member AUROPHARMA2021-04-012021-06-30in-bse-fin:OneOperatingExpenses02Member AUROPHARMA2021-04-012021-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares AUROPHARMA 2021-04-01 2022-03-31 2021-08-04 INR Lakhs First quarter Single segment Pharmaceutical Products 2021-04-01 2021-06-30 Unaudited Standalone 28937500000.00 270300000.00 29207800000.00 15434900000.00 59300000.00 -1117100000.00 4307700000.00 50600000.00 1146500000.00 5975400000.00 25857300000.00 3350500000.00 0.00 3350500000.00 1434400000.00 -234600000.00 1199800000.00 0.00 2150700000.00 0.00 0.00 0.00 0.00 2150700000.00 -16000000.00 2134700000.00 2134700000.00 0.00 585900000.00 1 3.67 3.67 0.00 0.00 3.67 3.67 1. The financial results of the Company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder. 2.The above standalone financial results as reviewed by the audit committee have been approved by the Board of Directors at its meeting held on 12 August 2021. The statutory auditors have carried out limited review of the above results for the quarter and year ended 30 June 2021. An unmodified report has been issued by them thereon. 3.The Company operates in only one segment viz., 'Pharmaceutical Products'. 4.Sales of standalone include exports of Rs.289,286 lakhs for the current quarter (30 June 2020: Rs.281,483 lakhs). 5.The Government of India, on 20 September 2019, vide the Taxation Laws (Amendment) Ordinance 2019, the Ordinance inserted a new Section 115BAA in the Income tax Act, 1961, which provides an option to the Company for paying income tax at reduced rates as per the provisions/conditions defined in the said section. The Company is in the process of evaluating the above ordinance and currently the management has proposed to continue with the old tax rates. 6.During the financial year 2019-20, the Board of directors of the Company has approved for amalgamation of the five subsidiary Companies with Aurobindo Pharma Limited, the holding company with the appointed date of 1 April 2019. Accordingly, a Scheme of Amalgamation for merger of APL Healthcare Limited, APL Research Centre Limited, Aurozymes Limited, Curepro Parenterals Limited, Hyacinths Pharma Private Limited and Silicon Life Sciences Private Limited (a stepdown wholly owned subsidiary) with the Company was filed before the Hon’ble National Company Law Tribunal, Hyderabad (NCLT). Further, during the previous year, a modified Scheme Amalgamation was filed with the Hon’ble NCLT by way of filing an Interlocutory application for removal and complete exclusion of the APL Healthcare Limited as a party to the Scheme of Amalgamation. The Hon’ble NCLT vide order dated 30 March 2021 has approved the modified scheme of amalgamation and a certified copy has been filed by the Company with the Registrar of Companies, Telangana 29 April 2021. Accordingly, the subsidiaries viz. APL Research Centre Limited, Aurozymes Limited, Curepro Parenterals Limited, Hyacinths Pharma Private Limited and Silicon Life Sciences Private Limited (a stepdown wholly owned subsidiary) have been merged with Aurobindo Pharma Limited. The appointed date as per the NCLT approved Scheme is 1 April 2019, which is the same as the beginning of the preceding period in the financial statements and hence, in line with the Scheme, the combination has been accounted for from that date as per the requirements of Appendix C to Ind AS 103 “Business Combination”. Accordingly, the amounts relating to the three months and year ended 31 March 2021 include the impact of the business combination and the corresponding amounts for three months ended 30 June 2020 shown in the statement, have been restated after recognising the effect of the Scheme as above. Impact of the Scheme on the statement of standalone results Particulars Quarter ended 30.06.2020 Year ended 31.03.2021 Total income 167 7,261 Total expenses 1,130 9,812 Loss before tax (963) (2,551) Tax expense/(benefit) (248) (657) (Loss) after tax (715) (1,894) 7 Foreign exchange gain includes exchange difference arising from foreign currency borrowings to the extent that they are regarded as an adjustment to finance cost as per para 6(e) of Ind AS 23 on borrowing costs. Foreign Exchange Gain -169200000.00 Other Expenses 6144600000.00 8 The Company continues to monitor the possible effects that may result from the pandemic relating to COVID-19. The Company continues to take several business continuity measures with a view to ensure minimal disruption with respect to operations including production and distribution activities. The Company has not experienced any significant difficulties with respect to market demand, financing capital expansion projects, collections or liquidity in other markets. Based on internal and external sources of information, current economic environment and future economic indicators, the Company has assessed the financial impact of the COVID-19 situation on its operations particularly on the carrying amounts of receivables, inventories, property, plant and equipment and intangible assets. Wherever considered necessary an assessment of the impact has been carried out and the necessary adjustments if material have been recorded. However, the impact of the pandemic could be different from those estimated today considering the uncertainties involved. The Company will continue to monitor any material changes to future economic conditions. 9 The Board of Aurobindo Pharma Limited on 27 February 2021 had approved the transfer of its oral formulations business comprised in Unit 10 located at Multiproduct Special Economic Zone, Naidupet, Mandal, SPSR Nellore District, Andhra Pradesh to its wholly-owned subsidairy APL Healthcare Limited through a slump sale. During the current quarter the above undertaking was transferred for consideration of Rs.131,500 lakhs. 10 The Board of Aurobindo Pharma Limited in their meeting held on 1st July 2021 approved the transfer of business undertaking comprised in Unit-4 of the Company, to Eugia Specialities Limited, a wholly owned subsidiary of the Company. The Company is in the process of getting necessary approvals from respective authorities. 11 The Board of Aurobindo Pharma Limited in their meeting held on 31st May 2021 approved Transfer of business undertaking comprised in Unit-16 of the Company, to Wytells Pharma Private Limited, a wholly owned step-down subsidiary of the Company and 100% subsidiary of Eugia Pharma Specialities. The Company is in the process of getting necessary approvals from respective authorities. Hence, no adjustment was made in the books of account for the quarter ended 30 June 2021. 12 The date of implementation of the Code of Wages 2019 and Code on Social Security, 2020 is yet to be notified by the Government. The Company is in the process of assessing the impact of these Codes and will give effect in the financial results when the Rules/Schemes thereunder are notified. 13 The figures of the quarter ended 31 March 2021 are the balancing figures between audited figures in respect of the full financial year upto 31 March 2021 and the unaudited published year to date figures upto 31 December 2020 being the date of the end of the third quarter of the financial year. The standalone results for the nine months ended 31 December 2020 have been subjected to the limited review by the statutory auditors. 14 The Board has approved interim dividend @150% i.e.Re.1.50 (Rupee one and fifty paise only) per equity share of Re.1 (Rupee One only) for the year 2021-22.